Table 2.
Distribution of ARE genetic variants by BPD outcomes in our cohort:
| Variant rs number |
No BPD (n=375) genotype frequency (%) |
BPD (n=284) genotype frequency (%) |
Severe BPD (n=135) genotype frequency (%) |
|---|---|---|---|
|
| |||
| GSTP1 rs1695 |
AA - 148 (39.6) | AA - 118 (41.8) | AA - 53 (39.3) |
| AG - 171 (45.7) | AG - 125 (44.3) | AG - 64 (47.4) | |
| GG - 55 (14.7) | GG - 39 (13.9) | GG - 18 (13.3) | |
|
| |||
| SOD2 rs4880 |
TT - 95 (25.5) | TT - 67 (23.8) | TT - 31 (23.3) |
| CT - 183 (49) | CT - 149 (52.8) | CT - 73 (54.9) | |
| CC - 95 (25.5) | CC - 66 (23.4) | CC - 29 (21.8) | |
|
| |||
| NQO1 rs1800566 |
CC - 222 (59.4) | CC - 173 (61.3) | CC - 83 (61.9) |
| CT - 138 (36.9) | CT - 88 (31.2) | CT - 41 (30.6) | |
| TT - 14 (3.7) | TT - 21 (7.5)* | TT - 10 (7.5) | |
|
| |||
| NFE2L2 rs6721961 |
CC - 289 (77.3) | CC - 226 (80.4) | CC - 116 (86.6) † |
| CA - 84 (22.5) | CA - 51 (18.2) | CA - 16 (11.9) | |
| AA - 1 (0.2) | AA - 4 (1.4) | AA - 2 (1.5) | |
|
| |||
| GCLC rs17883901 |
CC - 315 (84.2) | CC - 240 (85.1) | CC - 114 (85.7) |
| CT - 57 (15.2) | CT - 39 (13.8) | CT - 19 (14.3) | |
| TT - 2 (0.6) | TT - 3 (1.1) | TT - 0 | |
|
| |||
| HMOX1 rs2071747 |
GG - 344 (92.5) | GG - 254 (90) | GG - 120 (89.6) |
| GC - 27 (7.3) | GC - 26 (9.2) | GC - 13 (9.7) | |
| CC - 1 (0.2) | CC - 2 (0.8) | CC - 1(0.7) | |
Genotype frequencies of study subjects stratified by BPD outcome are presented. rs number; reference SNP accession ID number.
*
P=0.05 (BPD vs. infants without BPD; recessive model);
†
P=0.01 (severe BPD vs. infants without severe BPD; dominant model).
Genetic recessive model; two copies of the SNP is required to confer disease risk, genetic dominance model; a single copy of the SNP can confer disease risk.